Retavase Approved For Heart Attack Treatment In Canada
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Retavase Approved For Heart Attack Treatment In Canada

TORONTO, ON -- Sept. 15, 1998 -- Health Canada has approved Centocor Inc.’s Retavase™ (reteplase), a clot-busting fibrinolytic agent for use in patients suffering from heart attacks.

Biovail Corporation International will market the drug in Canada.

According to Health Canada cardiovascular disease is now the leading cause of death in Canada, accounting for 37 percent of all deaths. Ischemic heart disease (IHD) is responsible for the greatest percentage of deaths with 21 percent, of which half are attributable to acute myocardial infarction (AMI). Cardiovascular disease was the most expensive disease category according to 1995 statistics, representing $7.3 billion or 17 percent of the total direct costs of all illnesses.

Fibrinolytic agents are used to treat patients who suffer from heart attacks. Widespread research has shown that one of the most effective treatments for a heart attack caused by a blood clot is to quickly administer a fibrinolytic agent to restore blood flow to the affected artery. Retavase is the only fibrinolytic that can be administered through a simple two-shot injection rather than by way of a continuous intravenous infusion.

Related Links: Retavase, Centocor Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities